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Abstract
Background: Breast cancer patients with early-stage disease are increasingly administered neoadjuvant
chemotherapy (NAC) to downstage their tumors prior to surgery. In this setting, approximately 31% of patients fail
to respond to therapy. This demonstrates the need for techniques capable of providing personalized feedback
about treatment response at the earliest stages of therapy to identify patients likely to benefit from changing
treatment. Diffuse optical spectroscopic imaging (DOSI) has emerged as a promising functional imaging technique
for NAC monitoring. DOSI uses non-ionizing near-infrared light to provide non-invasive measures of absolute
concentrations of tissue chromophores such as oxyhemoglobin. In 2011, we reported a new DOSI prognostic
marker, oxyhemoglobin flare: a transient increase in oxyhemoglobin capable of discriminating NAC responders
within the first day of treatment. In this follow-up study, DOSI was used to confirm the presence of the flare as well
as to investigate whether DOSI markers of NAC response are regimen dependent.
Methods: This dual-center study examined 54 breast tumors receiving NAC measured with DOSI before therapy
and the first week following chemotherapy administration. Patients were treated with either a standard of care
maximum tolerated dose (MTD) regimen or an investigational metronomic (MET) regimen. Changes in tumor
chromophores were tracked throughout the first week and compared to pathologic response and treatment
regimen at specific days utilizing generalized estimating equations (GEE).
Results: Within patients receiving MTD therapy, the oxyhemoglobin flare was confirmed as a prognostic DOSI
marker for response appearing as soon as day 1 with post hoc GEE analysis demonstrating a difference of 48.77%
between responders and non-responders (p < 0.0001). Flare was not observed in patients receiving MET therapy.
Within all responding patients, the specific treatment was a significant predictor of day 1 changes in
oxyhemoglobin, showing a difference of 39.45% (p = 0.0010) between patients receiving MTD and MET regimens.
Conclusions: DOSI optical biomarkers are differentially sensitive to MTD and MET regimens at early timepoints
suggesting the specific treatment regimen should be considered in future DOSI studies. Additionally, DOSI may
help to identify regimen-specific responses in a more personalized manner, potentially providing critical feedback
necessary to implement adaptive changes to the treatment strategy.
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Background
Neoadjuvant chemotherapy (NAC) is an important treat-
ment strategy for breast cancer patients with early-stage
disease. NAC is used to downstage primary tumors and
its use has led to more breast-conserving surgeries [30].
Pathologic complete response (pCR) to NAC, defined as
the absence of invasive disease at the time of surgery,
has been accepted by the FDA as a surrogate endpoint
correlated with clinical benefit [17]. The use of pCR as
an endpoint in drug studies has the potential benefit of
evaluating efficacy much more rapidly than an endpoint
of progression-free survival or overall survival and has
recently led to accelerated approval of pertuzumab for
use in HER2-positive breast cancer in the NAC setting
[15]. Patients that fail to achieve pCR but have a sub-
stantial reduction in tumor size (> 50%) also receive
therapeutic benefit including a higher rate of breast-
conserving surgeries [1]. The combination of these
partial responders (PR) with pCR patients represent the
cohort most likely to benefit from NAC. Unfortunately,
31% of patients fail to respond to therapy [1]. These are
the patients most critical to identify so that their therapy
can be altered to avoid ineffective treatment and unwar-
ranted side effects.
The ongoing challenge of highly heterogeneous re-
sponses to cancer therapeutics, combined with the in-
creasing array of therapeutic agents and dosing
regimens, highlights the importance of tools that can
assist oncologists in personalizing, monitoring, and
adapting regimens to improve outcomes and limit
toxicity. Unfortunately, current methods to assess
treatment response, especially at early stages of treat-
ment, are limited [19]. Standard of care imaging mo-
dalities such as mammography, ultrasound, and MRI
provide anatomical information which has shown lim-
ited success in predicting response at early timepoints
[26, 34, 52]. Functional imaging modalities such as
FDG-PET [2], contrast enhanced MRI [41], and MRS
[11] have often demonstrated both earlier and im-
proved prognostic ability, but these modalities suffer
from high cost and/or necessity of contrast agents
making them impractical for frequent longitudinal
monitoring.
Diffuse optical spectroscopic imaging (DOSI) and dif-
fuse optical tomography (DOT) are emerging as afford-
able, non-invasive functional imaging modalities for
longitudinally monitoring breast tumors during NAC
[18, 47]. DOSI uses near-infrared light (650–1000 nm) to
interrogate tissue optical absorption and scattering prop-
erties up to several centimeters in depth [4, 40, 43].
DOSI measures absolute concentrations of oxyhemoglo-
bin, deoxyhemoglobin, lipid, and water. These parame-
ters have been shown by multiple research groups to be
valuable prognostic markers at various points
throughout NAC [6, 9, 16, 21, 27, 45, 46, 48, 49, 50, 53].
For example, a recent landmark multicenter study
(ACRIN 6691) showed that changes in tumor deoxyhe-
moglobin, water, and lipid at midpoint of NAC corre-
lated strongly to pCR [48]. Additionally, we have
previously shown that alterations in tumor oxyhemoglo-
bin during the first day of therapy can discriminate
responding from non-responding NAC patients, repre-
senting the earliest DOSI marker of treatment response
to date [45].
Importantly, almost all prior treatment monitoring
studies with DOSI and DOT have analyzed NAC treat-
ment response irrespective of regimen, representing a
substantial limitation in the field. The magnitude of anti-
angiogenesis, hypoxia, immune activation, and other bio-
logical effects induced by systemic therapies are highly
dependent on the specific agents and treatment sched-
ules [3, 28, 50]. Consequently, DOSI and DOT prognos-
tic biomarkers may be highly dependent on the
particular agents and schedule. Current standard of care
NAC regimens most commonly utilize maximum toler-
ated dosing (MTD) [37]. MTD is defined as the highest
dose that can be administered without unacceptable side
effects. This strategy relies on the kinetics of large doses
of drug administrations leading to dramatic tumor cyto-
toxicity, typically followed by a rest period in which the
host recovers from off-target effects [22]. In this para-
digm, non-responding patients can endure up to several
months of severe cytotoxic side effects without any
therapeutic benefit. Alternative treatment dosing sched-
ules are currently being explored to both enhance thera-
peutic efficacy and reduce off-target toxicity. Perhaps
most importantly, metronomic (MET) scheduling, which
utilizes lower-dose agents administered more frequently,
has demonstrated promising anti-angiogenic properties
[29, 42] as well as antitumor immune activation while
limiting side effects [28, 33, 36]. There continues to be
considerable interest in investigating whether MET regi-
mens can improve response rates and outcomes in
breast and other cancers, demonstrated by the dozens of
active clinical studies exploring metronomic regimens
listed on www.clinicaltrials.gov.
We present here clinical evidence of regimen-
specific DOSI response during early NAC, demon-
strating that the oxyhemoglobin flare, a transient
increase in tumor oxyhemoglobin concentration oc-
curring during the first week of NAC, manifests as a
powerful prognostic marker in patients receiving an
MTD regimen, but fails to appear in a well-matched
MET cohort. In MTD patients, oxyhemoglobin flare
peaked 24 h following the first chemotherapy infusion.
This work highlights the importance of precision
treatment monitoring strategies that account for the
specific therapeutic regimen.
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Methods
Spectroscopy
Specific details about the DOSI instrumentation have
been well described elsewhere [4]. Briefly, DOSI uses
near-infrared light (650–1000 nm) to measure deep tis-
sue functional information with a handheld probe. For
this study, fiber-coupled temporally modulated laser di-
odes (659, 689, 781, 829 nm or 658, 682, 785, 810, 830,
850 nm) and a broadband near-infrared light source
(650–1000 nm) were used to illuminate the tissue from
the skin surface. An avalanche photodiode was used to
detect the remitted temporally modulated laser light and
a spectrometer was used to measure the remitted broad-
band light. The lasers were frequency swept from 50 to
400MHz; the amplitude and phase perturbations in-
duced by the tissue were measured with a vector net-
work analyzer or custom analog electronics [39]. The
amplitude and phase at each wavelength and modulation
frequency were fit to an analytical solution to the P1 dif-
fusion approximation of the Boltzmann transport equa-
tion solved in the frequency-domain with semi-infinite
boundary conditions [24]. This information was com-
bined with broadband diffuse reflectance measurements
to yield broadband optical absorption and reduced scat-
tering properties [4]. Absolute concentrations of oxy-
hemoglobin (HbO2), deoxyhemoglobin (HHb), water,
and lipid were then determined by a least squares fitting
procedure of the broadband absorption spectra to the
known extinction coefficient spectra of these four chro-
mophores according to Beer’s law. Additional composite
metrics were also computed including total hemoglobin
(THb = HbO2 +HHb), oxygen saturation (StO2 = HbO2
/THb), and tissue optical index (TOI = HHb × water/
lipid). All data analysis was conducted using custom pro-
cessing codes developed in MATLAB R2014b (Math-
Works Inc).
Imaging procedure
DOSI scans were conducted prior to chemotherapy ad-
ministration (baseline) and as many days as possible
within the first week of starting therapy dependent on
patient availability and health status. A standardized
DOSI measurement protocol was used to measure the
patients [48]. Briefly, a sequential rectangular grid pat-
tern with 1-cm spacing was transferred to the tissue
using a transparency and surgical marker. The DOSI
probe was placed against the breast and a measurement
was taken at every point on the grid. Landmarks such as
the nipple, areola, freckles, and moles were used to cor-
egister longitudinal measurements. The size of the rect-
angular grid was chosen to fully include the tumor
region with clear margins as determined by prior stand-
ard of care imaging and palpation. An example of a
measurement grid is shown in Fig. 1 on the left breast
using a 3D bust model. An interpolated heatmap of the
TOI composite metric in shown over the right breast
over a 3.7-cm tumor. The tumor and areola both show
significant TOI contrast relative to the surrounding
breast tissue, a highly conserved feature seen across
many breast cancer subjects [7].
Image analysis
2D heatmaps of each chromophore (i.e., HbO2, HHb,
water, lipid) and composite metrics (i.e., THb, StO2,
TOI) were generated for each subject and at each time
point. A tumor region of interest (ROI) was determined
using a combination of peak TOI contrast, as described
by previous studies [6, 7, 48], and tumor size was deter-
mined by ultrasound or MRI. The tumor ROI size
remained constant throughout the longitudinal measure-
ments but was allowed to laterally shift in cases of grid
displacement. Tumor chromophore concentrations were
calculated by taking the mean over the tumor ROI.
Subject eligibility and enrollment
A total of 53 female breast cancer patients were mea-
sured at Boston Medical Center (BMC) and University
of California, Irvine (UCI) from May 2004 to October
2017. Subject’s ages ranged from 26 to 71. One patient
had bilateral breast cancer with both tumors measured
for a total of 54 DOSI monitored tumors. Eligible sub-
jects had a diagnosis of invasive breast cancer and were
planned for neoadjuvant cytotoxic chemotherapy with
definitive breast surgery following therapy. Each patient’s
treatment regimen was determined by their oncologist; a
subset of subjects was simultaneously enrolled in an
Fig. 1 Bust model of DOSI measurement. Example of DOSI
measurement grid locations (right) and subsequent TOI map (left)
demonstrating tumor and areolar contrast
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investigational protocol testing MET dosing and sched-
uling (Clinicaltrials.gov Identifier NCT00618657). The
patients received a biopsy prior to treatment to confirm
invasive cancer diagnosis, which provided the tumor re-
ceptor status (i.e., ER, PR, HER2). Potential subjects were
excluded if they were pregnant or previously received
treatment to the affected breast. Data from a portion of
these 54 subjects had been used in prior published
works, including the initial observation of oxyhemoglo-
bin flare [45], which analyzed 24 of the current 54 sub-
jects throughout week 1, including day 1. The remaining
30 subjects’ data at day 1 have not been published be-
fore, although 14 of the current 54 subjects were also
enrolled in the ACRIN 6691 study [10, 48], which in-
cluded baseline, early (days 5–10), midpoint, and pre-
surgical timepoint measurements. All patients provided
written informed consent. This project was approved by
the Institution Review Board at Boston University, Bos-
ton Medical Center and UCI.
Histopathology
Each patient’s resected tumor was evaluated by the local
institution’s pathologist to generate a pathology report.
After treatment, the patient was assigned a tertiary re-
sponse status according to the National Surgical Adju-
vant Breast and Bowel Project Protocol [44]: pathologic
complete response (pCR), partial response (PR), and no
response (NR). pCR was defined as no residual tumor
burden in resected tumor. PR was defined as a decrease
in the largest tumor dimension by > 50% from diagnosis
to resection while NR was defined as a decrease of <
50%. A binary classification of response was also utilized
in which responders, defined as subjects achieving either
pCR or PR, were compared against NR subjects.
Statistical analysis
Generalized estimating equations (GEE) were used to
longitudinally model the DOSI chromophores through-
out the first week after chemotherapy utilizing SAS (SAS
Institute) [31]. The GEE accounted for the correlation
between multiple measurements on a single patient and
allowed for an unbalanced dataset with subjects consid-
ered as clusters, an exchangeable correlation structure,
and a normal model with an identity link function. Sep-
arate models were run on each of four chromophores:
HbO2, HHb, water, and lipid. In addition, for each out-
come variable, three separate models were run on popu-
lation stratifications of treatment schedule and
pathologic response to isolate the effects of specific co-
variates and interaction terms: (1) MTD responders vs
MTD non-responders, (2) MET responders vs MET
non-responders, and (3) MTD responders vs MET re-
sponders. Additional covariates included in these models
included as follows: institution (Boston Medical Center
vs UC Irvine), age, hormone receptor status (estrogen
receptor or progesterone receptor), and HER2 status.
Significance for model parameters was determined at a
level of 0.05 and when adjusted for multiple compari-
sons with Bonferroni correction at a level of 0.0125.
Additional covariates relating to treatment such as che-
motherapeutic agent or drug mechanism were not in-
cluded as these parameters were highly correlated with
treatment schedule (e.g., all patients administered adria-
mycin + cyclophosphamide received an MTD schedule).
Post hoc contrasts between outcome means adjusted for
covariates in the statistical models were performed at
each day post chemotherapy between strata of interest:
(1) MTD: responders vs non-responders and (2) re-
sponders: MTD vs MET. Significance for post hoc con-
trasts, when adjusted for multiple comparisons with
Bonferroni correction, was determined at a level of
0.0036.
Linear discriminant analysis (LDA) was performed
using MATLAB to assess the prognostic accuracy of
percent change in oxyhemoglobin on day 1 among MTD
and MET population. This analysis assumed multivariate
normal densities and equal covariance for each group.
Fivefold cross-validation was used to train and test the
dataset and limit overfitting. We note that there was ap-
proximately twice as many responders as non-
responders in the MTD cohort and no efforts were made
to account for this imbalance in the classification ana-
lysis. Posterior probabilities were calculated for each
subject from the linear classification of responders from
non-responders. Receiver operating characteristic (ROC)
curves were generated by iterating through all posterior
probability thresholds. The area under the curve (AUC)
of the ROC curve was utilized to evaluate the perform-
ance of the model along with the optimal sensitivity,
specificity, positive predictive value (PPV), and negative
predictive value (NPV).
Results
Subject and treatment characteristics
The characteristics of all analyzed subjects are shown in
Table 1, which shows the overall population (n = 54) sta-
tistics as well as characteristics stratified by treatment
schedule: maximum tolerated dose (MTD, n = 35) and
metronomic (MET, n = 19). The MTD patients received
treatment every 2 or 3 weeks at the highest dose without
unacceptable side effects per the standard of care. In
contrast, MET patients received treatment every week at
a smaller dose than MTD. The average overall subject
age was 49.9 ± 11.1 years with a slightly higher age
among the MTD subset, 51.3 ± 11.1 years and slightly
lower in MET subset, 47.4 ± 10.8 years. The average
tumor size was 3.5 ± 1.7 cm for all subjects, 3.8 ± 1.9 cm
for MTD subjects, and with 3.0 ± 1.3 cm MET subjects.
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Age and tumor size were not significantly different (p >
0.05) between the MTD and MET cohort through the
Wilcoxon rank sum test using MATLAB, utilizing a
nonparametric test to avoid any assumptions of the
underlying distributions.
All patients received a diagnosis of invasive carcinoma
with the majority of patients (91%) receiving a diagnosis
of invasive ductal carcinoma (IDC). In total, 65% of sub-
jects had hormone receptor-positive tumors. Fifteen sub-
jects were diagnosed with HER2-positive tumors; of
those, seven received trastuzumab (Tr) as part of their
first neoadjuvant treatment and the other eight received
Tr at a timepoint which was not in the scope of this
study. Within the MTD treatment schedule, one patient
received a combination of HER2-targeted therapies with
both Tr and pertuzumab (Pzb) along with the cytotoxic
agent docetaxel (DTX). One MTD patient received a
combination of carboplatin (Cb), DTX, and Tr. Three
MTD patients received adriamycin (A) + cyclophospha-
mide (C) + DTX, while 30 MTD patients received A + C,
which is the current standard of care therapy. Among
the MET patients, 14 patients received carboplatin
(Cb) + paclitaxel (nPTX) + bevacizumab (Bev) and 5 pa-
tients received Cb + nPTX + Tr.
At the time of surgery, 35 patients (65%) were deter-
mined to be responders while 19 patients (35%) were
non-responders. A total of 71% of MTD patients were
responders (n = 25) and 53% of MET patients were re-
sponders (n = 10). All proportions (location, histology,
receptor status, and pathologic response) were not sig-
nificantly different between MTD and MET cohorts (p >
0.05) using the Z-Test for proportions implemented in
MATLAB.
DOSI reveals response and regimen-dependent HbO2
changes on day 1 of NAC
The percent change from baseline was examined to
normalize for varying baseline tumor chromophore con-
centrations among patients, with a focus on the primary
aim of day 1 postchemotherapy changes. The observed
changes across week 1 are shown in Fig. 2. For subjects
receiving MTD treatment, the largest difference between
responders and non-responders occurred on day 1. Re-
sponders on day 1 demonstrated a mean 40% increase in
HbO2 at day 1 compared to a 13% decrease in non-
responders. All MET subjects displayed much smaller
changes on day 1: responders with a 3% increase and
non-responders with a 1% decrease. These differences
are visualized in Fig. 3, which shows representative 2D
DOSI heatmaps of HbO2 concentrations at both baseline
and day 1 for two different pCR subjects, one of whom
received MTD treatment while the other received MET
therapy. The MTD patient had a large increase of 50%
in HbO2 from baseline to day 1 contrasted with the
Table 1 Subject and tumor characteristics
Variables Treatment cohorts
Maximum tolerable
dose (n = 35)
Metronomic
dose (n = 19)
Overall
(n = 54)
Age (years)
Mean ± SD 51.3 ± 11.1 47.4 ± 10.8 49.9 ±
11.1
Tumor Size (cm)
Mean ± SD 3.8 ± 1.9 3.0 ± 1.3 3.5 ± 1.7
Location
Left 15 (43%) 10 (53%) 25 (46%)
Right 20 (57%) 9 (47%) 29 (54%)
Histology
IDC 31 (89%) 18 (95%) 49 (91%)
ILC 4 (11%) 1 (5%) 5 (9%)
Receptor status
ER
− 13 (37%) 5 (26%) 18 (33%)
+ 21 (60%) 14 (74%) 35 (65%)
PR
− 15 (42%) 8 (42%) 23 (43%)
+ 19 (54%) 11 (58%) 30 (56%)
HER2
− 24 (69%) 14 (74%) 38 (70%)
+ 10 (29%) 5 (26%) 15 (28%)
Unknown
receptor (ER,PR,
HER2)
1 (2%) 0 1 (2%)
Pathologic response
Complete response 10 (29%) 5 (26%) 15 (28%)
Partial response 15 (43%) 5 (26%) 20 (37%)
No response 10 (29%) 9 (47%) 19 (35%)
Treatment
AC 30 (86%) 0 30 (56%)
AC + DTX 3 (9%) 0 3 (6%)
Cb + DTX + Tr 1 (3%) 0 1 (2%)
Cb + nPTX+Bev 0 14 (74%) 14 (26%)
Cb + nPTX+Tr 0 5 (26%) 5 (9%)
Pzb + DTX + Tr 1 (3%) 0 1 (2%)
Institute
UC Irvine 29 (83%) 19 (100%) 48 (89%)
Boston Medical
Center
6 (17%) 0 6 (11%)
Abbreviations: IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, ER
estrogen receptor, PR progesterone receptor, HER2 Human Epidermal Growth
Factor Receptor 2, AC adriamycin and cyclophosphamide, DTX docetaxel, Cb
carboplatin, Tr trastuzumab, nPTX paclitaxel, Bev bevacizumab,
Pzb pertuzumab
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MET patient, which only increased by 0.3%. In addition,
there were relatively small changes in both MET re-
sponders and non-responders across the entire week 1
as compared to the MTD patients.
Separate GEE models were fit for the MTD and MET
subject populations to isolate the effect of treatment and
evaluate the effects of age, institution, hormone receptor
status, HER2 status, days post chemotherapy, response,
and the corresponding interaction terms. Within the
MTD cohort, the interaction term of response and day 1
was a significant predictor of HbO2 (p < 0.0001) while
the MET cohort failed to demonstrate a statistically sig-
nificant predictor. In order to isolate the effect of patho-
logic response, a separate GEE model was run on the
responder population to determine the effects of age, in-
stitution, hormone receptor status, HER2 status, days
post chemotherapy, treatment schedule, and the corre-
sponding interaction terms. The interaction term of
treatment schedule and day 1 was a significant predictor
of HbO2 (p = 0.0008) in responders. Post hoc analysis of
outcome adjusted estimates to compare the effect of
treatment demonstrated a significant difference in day 1
HbO2 changes between MTD responders and MET re-
sponders (39.45 ± 11.98%, p = 0.0010) seen in Add-
itional file 1: Table S1A. Similar analysis on the efficacy
Fig. 2 Week 1 postchemotherapy changes of DOSI-monitored tumors. Percent change in oxyhemoglobin during the first week
postchemotherapy separated by treatment: maximum tolerated dose (left) and metronomic (right) and pathologic response: responders (dark
gray, solid line) and non-responders (light gray, dashed). At day 1, MTD responders and non-responders are significantly different (p < 0.0001),
while MET subjects fail to demonstrate a statistical difference. Number of subjects measured at each timepoint is indicated and color-coded for
pathologic response. Error bars indicate mean ± standard error
Fig. 3 Map of oxyhemoglobin flare and regimen-specific response.
Interpolated HbO2 maps at baseline (left column) and day 1 (right
column) for two pathologic complete responder patients receiving
maximum tolerated dose (top) and metronomic (bottom). The
tumor region is indicated by the dashed circle with the scale bar
indicating 1 cm. The percent change from baseline for the entire
tumor region is indicated in the day 1 column showing
oxyhemoglobin flare in MTD patient while MET patient showed
almost no change
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of HbO2 as a prognostic biomarker at day 1 for patients
receiving MTD demonstrated a difference of 48.77 ±
9.51% (p < 0.0001) between responders and non-
responders seen in Additional file 1: Table S1B. None of
the additional covariates (age, institution, hormone re-
ceptor status, HER2 receptor status) contributed signifi-
cantly to the model.
Separate LDAs were run on the MTD and MET sub-
ject populations to evaluate HbO2 performance on day 1
as a prognostic predictor when isolating the effect of
treatment, results shown in Additional file 2: Figure S1.
The MTD cohort had an AUC of 0.89, sensitivity of
0.91, specificity of 0.89, PPV of 0.95, and NPV of 0.80.
In stark contrast, the MET cohort had an AUC of 0.50,
sensitivity of 0.50, specificity of 0.75, PPV of 0.71, and
NPV of 0.55.
DOSI measured changes in HHb, water, and lipid
throughout week 1 of NAC
HHb, water, and lipid did not exhibit significant
prognostic or regimen-dependent changes in either
MTD or MET patients. GEE analysis was run on
these chromophores for each of the three population
stratifications and there were no significant interac-
tions of treatment or response at any day. The most
notable interaction term was response and day 1 post
chemotherapy (p = 0.0136) for water in MTD patients,
which came close to significance (p < 0.0125 for Bon-
ferroni correction). At this timepoint, non-responding
MTD patients had a moderate decrease in water con-
centration compared to responders (Additional file 3:
Figure S2).
Discussion
Early prediction of NAC response would provide import-
ant feedback to alter the therapeutic regimen for each in-
dividual patient. We have demonstrated here that early
DOS imaging markers are dependent on the specific NAC
regimen administered. Specifically, MTD and MET regi-
mens resulted in significantly different oxyhemoglobin re-
sponses throughout week 1 of NAC. Oxyhemoglobin
flare, a previously reported prognostic biomarker for ther-
apy response, manifested only in MTD-treated breast tu-
mors, while MET treatment yielded almost no
hemodynamic changes across throughout week 1, regard-
less of response.
There have been few clinical monitoring studies of
breast cancer patients at the earliest timepoints of
neoadjuvant chemotherapy. Clinical studies utilizing
magnetic resonance spectroscopy [35] and FDG-PET
[12] have previously observed a prognostic metabolic
change within 1 day of therapy. The authors of the
MRS study hypothesized that responding tumors re-
ceiving AC treatment underwent cytotoxicity and/or
decreases in tumor proliferation at day 1, while the au-
thors of the FDG-PET study demonstrated increased
metabolic activity in responsive tumors on day 1. Our
group has previously demonstrated the presence of the
oxyhemoglobin flare on day 1, which provided dis-
crimination of responders from non-responders in a
cohort of 24 subjects, 21 of whom received MTD regi-
mens [45]. The present study included data from these
prior subjects with the addition of 14 additional MTD
subjects and 16 additional MET subjects. Eleven new/
previously unpublished MTD patients were measured
on day 1, of which 3/5 responders displayed flare and
5/6 non-responders did not display flare, (no increase
in oxyhemoglobin). In aggregate of all MTD patients,
HbO2 served as a strong predictor of NAC response
with an AUC of 0.89.
Most strikingly, the oxyhemoglobin flare was only
present in the subjects who received an MTD regi-
men, failing to manifest in subjects treated with a
MET regimen and serving as a poor predictor of re-
sponse with an AUC of 0.50. In MET subjects, only
small (< 11%) changes in oxyhemoglobin were ob-
served across the entire week 1 of therapy and no
prognostic changes occurred in any of the other
hemodynamic parameters including deoxyhemoglobin,
total hemoglobin, and oxygen saturation. The pres-
ence of oxyhemoglobin flare in responding MTD sub-
jects and a lack of hemodynamic response in both
non-responding MTD subjects and all MET subjects
suggest a distinct physiological reaction in responding
MTD patients. A rise in oxyhemoglobin may occur
due to either a decrease in tumor oxygen demand or
an increase in tumor oxygen supply. Subjects that ex-
perienced flare had a relatively small change in deox-
yhemoglobin leading to an increase in total
hemoglobin and oxygen saturation (Additional file 3:
Figure S2), indicating an increase in oxygen supply.
This would be consistent with the increased perfusion
known to co-occur with an inflammatory response to
cytotoxic cellular damage [5, 20, 25, 32, 38, 51]. The
lack of oxyhemoglobin flare in MTD NR patients may
indicate poor chemo- and/or immuno-responsiveness,
leading to minimal shrinkage of the tumor and poten-
tially poorer outcomes [13, 23].
MET therapy is characterized by the administration of
lower-dosage therapy with increased frequency. In this
study, the low initial dose may have been insufficient to
induce oxyhemoglobin flare, even in subjects who went on
to achieve partial or complete responses. Additionally,
MET regimens have been shown to exhibit substantially
different anti-angiogenic and immunomodulatory effects
compared to MTD [3, 8, 14, 22, 28, 36, 42]. Additionally,
14 of the 19 MET subjects received the VEGF-A targeting
drug bevacizumab in addition to cytotoxic therapies.
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Clinical administration of bevacizumab as a monotherapy
has been shown to cause hypoxia and decreased total
hemoglobin on day 1 when measured with a time-domain
diffuse optical system [50]. It is possible the administration
of bevacizumab inhibited oxyhemoglobin flare in respond-
ing MET subjects. These varying mechanisms of actions
may help to explain the lack of early hemodynamic re-
sponses observed in MET patients in this study. Notably,
several other publications [6, 10, 48, 49] included subjects
enrolled in the same investigational MET trial, although
the DOSI measurement timepoints investigated in these
studies did not include day 1 measurements.
This retrospective study did not control for chemo-
therapeutic agents as patients across and in the MTD
and MET cohorts received different agents as well as
scheduling and dosing. The standard of care for NAC
allows for flexibility in the order of agents and the
exact regimen, determined by the oncologist. This
further demonstrates the necessity to account for all
aspects of the treatment regimen when investigating
prognostic biomarkers. The combination of different
agents and dosing strategies may yield different syner-
gistic mechanisms of action, ultimately affecting the
induction of oxyhemoglobin flare. Within the MTD
cohort, most patients received AC; however, some re-
ceived additional DTX, representing a potential con-
founding variable. In the MET cohort, patients were
given differing targeted agents, either Bev or Tr. Sec-
ondary methods may be necessary to confirm the
exact biological origins of the flare through inflamma-
tory and immune markers. Additional potential future
analysis steps include a Z-score analysis like that con-
ducted by Cochran et al. in their analysis of DOSI
measurements at early timepoints (within days 5–10
of the start of treatment), as well as determining if
treatment schedule plays a significant factor at later
DOSI measurement timepoints [10].
Conclusion
In summary, we have demonstrated regimen-dependent
hemodynamic responses during week 1 of NAC. Oxy-
hemoglobin flare manifested as a prognostic marker
only in an MTD cohort and not in a MET cohort. This
is important as DOSI and DOT treatment monitoring
studies have traditionally aggregated subjects irrespect-
ive of treatment, while different regimens have mark-
edly different biological mechanisms of action. Early
regimen-specific DOSI prognostic markers could be
critical for improving patient outcome by identifying
non-responders and adapting therapy accordingly.
DOSI may also provide valuable feedback of investiga-
tional drug regimens and their proposed mechanisms
of action.
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